Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data

DOI record: { "DOI": "10.3390/jcm12010034", "ISSN": [ "2077-0383" ], "URL": "http://dx.doi.org/10.3390/jcm12010034", "abstract": "<jats:p>Concerns have been raised about the actual benefit and safety of molnupiravir, a new antiviral treatment for coronavirus disease 2019 (COVID-19). In order to provide additional evidence to support its use, we aimed to evaluate the real safety profile based on post-marketing pharmacovigilance data. Molnupiravir safety data were captured from the FDA Adverse Event Reporting System (FAERS). We performed a descriptive analysis of the baseline demographic characteristics of patients who experienced at least one adverse drug reaction (ADRs) related to molnupiravir, and then evaluated those most frequently reported. As of 31 March 2022, 612 reports of ADRs related to molnupiravir were submitted to the FDA, 301 (49.18%) were related to females and 281 (45.92%) to males. Most reports (524; 85.62%) were submitted by healthcare professionals and 345 (56.37%) concerned serious outcomes. The most common reported ADRs were diarrhoea (57; 4.51%), rash (36; 2.85), nausea (29; 2.30%), and COVID-19 pneumonia (22; 1.74%). The most frequent adverse reactions reported with molnupiravir in the U.S. post-marketing experience are consistent with the safety evaluation of the antiviral medicine. Even if no evident safety concerns emerged, an unexpectedly high rate of serious adverse reactions together with a few cases of potential new adverse reactions occurred.</jats:p>", "alternative-id": [ "jcm12010034" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-7897-2956", "affiliation": [], "authenticated-orcid": false, "family": "Santi Laurini", "given": "Greta", "sequence": "first" }, { "ORCID": "http://orcid.org/0000-0002-5710-8077", "affiliation": [], "authenticated-orcid": false, "family": "Montanaro", "given": "Nicola", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-6253-4014", "affiliation": [], "authenticated-orcid": false, "family": "Motola", "given": "Domenico", "sequence": "additional" } ], "container-title": "Journal of Clinical Medicine", "container-title-short": "JCM", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 12, 21 ] ], "date-time": "2022-12-21T08:31:06Z", "timestamp": 1671611466000 }, "deposited": { "date-parts": [ [ 2022, 12, 23 ] ], "date-time": "2022-12-23T09:33:52Z", "timestamp": 1671788032000 }, "indexed": { "date-parts": [ [ 2022, 12, 24 ] ], "date-time": "2022-12-24T06:08:15Z", "timestamp": 1671862095015 }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2022, 12, 21 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2023, 1 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 12, 21 ] ], "date-time": "2022-12-21T00:00:00Z", "timestamp": 1671580800000 } } ], "link": [ { "URL": "https://www.mdpi.com/2077-0383/12/1/34/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "34", "prefix": "10.3390", "published": { "date-parts": [ [ 2022, 12, 21 ] ] }, "published-online": { "date-parts": [ [ 2022, 12, 21 ] ] }, "publisher": "MDPI AG", "reference": [ { "key": "ref_1", "unstructured": "World Health Organization (2022, July 28). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/." }, { "DOI": "10.1016/j.coviro.2021.06.003", "article-title": "Developing a direct acting, orally available antiviral agent in a pandemic: The evolution of molnupiravir as a potential treatment for COVID-19", "author": "Painter", "doi-asserted-by": "crossref", "first-page": "17", "journal-title": "Curr. Opin. Virol.", "key": "ref_2", "volume": "50", "year": "2021" }, { "DOI": "10.1016/j.jbc.2021.100770", "article-title": "Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template", "author": "Gordon", "doi-asserted-by": "crossref", "first-page": "100770", "journal-title": "J. Biol. Chem.", "key": "ref_3", "volume": "297", "year": "2021" }, { "DOI": "10.1038/s41594-021-00651-0", "article-title": "Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis", "author": "Kabinger", "doi-asserted-by": "crossref", "first-page": "740", "journal-title": "Nat. Struct. Mol. Biol.", "key": "ref_4", "volume": "28", "year": "2021" }, { "DOI": "10.1056/NEJMoa2116044", "article-title": "Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients", "author": "Musungaie", "doi-asserted-by": "crossref", "first-page": "509", "journal-title": "N. Engl. J. Med.", "key": "ref_5", "volume": "386", "year": "2022" }, { "DOI": "10.1093/infdis/jiab247", "article-title": "β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "415", "journal-title": "J. Infect. Dis.", "key": "ref_6", "volume": "224", "year": "2021" }, { "key": "ref_7", "unstructured": "Food and Drug Administration (2022, July 21). Fact Sheet for Healthcare Providers: Emergency Use Authorization For LAGEVRIO™ (molnupiravir) Capsules, Available online: https://www.fda.gov/media/155054/download." }, { "DOI": "10.1056/NEJMoa2107934", "article-title": "Early Treatment for COVID-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab", "author": "Gupta", "doi-asserted-by": "crossref", "first-page": "1941", "journal-title": "N. Engl. J. Med.", "key": "ref_8", "volume": "385", "year": "2021" }, { "DOI": "10.1056/NEJMoa2102685", "article-title": "Bamlanivimab plus Etesevimab in Mild or Moderate COVID-19", "author": "Dougan", "doi-asserted-by": "crossref", "first-page": "1382", "journal-title": "N. Engl. J. Med.", "key": "ref_9", "volume": "385", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2022.6920", "article-title": "Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19", "author": "McCreary", "doi-asserted-by": "crossref", "first-page": "e226920", "journal-title": "JAMA Netw. Open", "key": "ref_10", "volume": "5", "year": "2022" }, { "DOI": "10.1093/ofid/ofac053", "article-title": "Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019", "author": "Preotescu", "doi-asserted-by": "crossref", "first-page": "ofac053", "journal-title": "Open Forum. Infect. Dis.", "key": "ref_11", "volume": "9", "year": "2022" }, { "DOI": "10.1101/2022.03.10.22272100", "doi-asserted-by": "crossref", "key": "ref_12", "unstructured": "Dougan, M., Azizad, M., Chen, P., Feldman, B., Frieman, M., Igbinadolor, A., Kumar, P., Morris, J., Potts, J., and Baracco, L. (2022). Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. MedRxiv, preprint." }, { "DOI": "10.1038/s41591-021-01294-w", "article-title": "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies", "author": "Chen", "doi-asserted-by": "crossref", "first-page": "717", "journal-title": "Nat. Med.", "key": "ref_13", "volume": "27", "year": "2021" }, { "DOI": "10.1038/s41586-021-04389-z", "article-title": "Considerable escape of SARS-CoV-2 Omicron to antibody neutralization", "author": "Planas", "doi-asserted-by": "crossref", "first-page": "671", "journal-title": "Nature", "key": "ref_14", "volume": "602", "year": "2022" }, { "DOI": "10.1128/JVI.01348-19", "article-title": "Small-Molecule Antiviral β-d- N 4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance", "author": "Agostini", "doi-asserted-by": "crossref", "first-page": "e01348-19", "journal-title": "J. Virol.", "key": "ref_15", "volume": "93", "year": "2019" }, { "article-title": "543 Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies. Open Forum", "author": "Grobler", "first-page": "S373", "journal-title": "Infect. Dis.", "key": "ref_16", "volume": "8", "year": "2021" }, { "key": "ref_17", "unstructured": "Merck (2022, June 21). Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Available online: https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/." }, { "key": "ref_18", "unstructured": "Medicines and Healthcare Products Regulatory Agency (2022, June 08). Regulatory Approval of Lagevrio (molnupiravir), Available online: https://www.gov.uk/government/publications/regulatory-approval-of-lagevrio-molnupiravir." }, { "DOI": "10.1136/bmj.n2697", "article-title": "COVID-19: UK becomes first country to authorise antiviral molnupiravir", "author": "Mahase", "doi-asserted-by": "crossref", "first-page": "n2697", "journal-title": "BMJ", "key": "ref_19", "volume": "375", "year": "2021" }, { "key": "ref_20", "unstructured": "Food and Drug Administration (2022, June 08). Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults, Available online: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain." }, { "key": "ref_21", "unstructured": "European Medicines Agency (2022, June 08). EMA Issues Advice on Use of Lagevrio (molnupiravir) for the Treatment of COVID-19. Available online: https://www.ema.europa.eu/en/news/ema-issues-advice-use-lagevrio-molnupiravir-treatment-covid-19." }, { "DOI": "10.1136/bmj.o1030", "article-title": "Molnupiravir might be dangerous without clarification of its indications", "author": "Hayashi", "doi-asserted-by": "crossref", "first-page": "o1030", "journal-title": "BMJ", "key": "ref_22", "volume": "377", "year": "2022" }, { "DOI": "10.1136/bmj.o443", "article-title": "Molnupiravir’s authorisation was premature", "author": "Brophy", "doi-asserted-by": "crossref", "first-page": "o443", "journal-title": "BMJ", "key": "ref_23", "volume": "376", "year": "2022" }, { "article-title": "Re: Molnupiravir’s authorisation was premature", "author": "Hill", "first-page": "o443", "journal-title": "BMJ", "key": "ref_24", "volume": "376", "year": "2022" }, { "article-title": "Re: Molnupiravir’s authorisation was premature", "author": "Etminan", "first-page": "o443", "journal-title": "BMJ", "key": "ref_25", "volume": "376", "year": "2022" }, { "article-title": "Re: Molnupiravir’s authorisation was premature", "author": "Hama", "first-page": "o443", "journal-title": "BMJ", "key": "ref_26", "volume": "376", "year": "2022" }, { "DOI": "10.4269/ajtmh.21-1339", "article-title": "Making Statistical Sense of the Molnupiravir MOVe-OUT", "author": "Thorlund", "doi-asserted-by": "crossref", "first-page": "1301", "journal-title": "Clin. Trial. Am. J. Trop Med. Hyg.", "key": "ref_27", "volume": "106", "year": "2022" }, { "key": "ref_28", "unstructured": "Food and Drug Administration (2022, June 16). FDA Adverse Event Reporting System (FAERS) Public Dashboard, Available online: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard." }, { "DOI": "10.1016/j.jsps.2013.02.003", "article-title": "Factors affecting the development of adverse drug reactions", "author": "Alomar", "doi-asserted-by": "crossref", "first-page": "83", "journal-title": "Saudi Pharm. J.", "key": "ref_29", "volume": "22", "year": "2014" }, { "DOI": "10.1177/2042098615615472", "article-title": "Predicting risk of adverse drug reactions in older adults", "author": "Lavan", "doi-asserted-by": "crossref", "first-page": "11", "journal-title": "Adv. Drug Saf.", "key": "ref_30", "volume": "7", "year": "2016" }, { "DOI": "10.7326/M22-0729", "article-title": "Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19: A Randomized, Placebo-Controlled Trial", "author": "Johnson", "doi-asserted-by": "crossref", "first-page": "1126", "journal-title": "Ann. Intern. Med.", "key": "ref_31", "volume": "175", "year": "2022" }, { "article-title": "Determine the most common clinical symptoms in COVID-19 patients: A systematic review and meta-analysis", "author": "Alimohamadi", "first-page": "E304", "journal-title": "J. Prev Med. Hyg.", "key": "ref_32", "volume": "61", "year": "2020" }, { "key": "ref_33", "unstructured": "Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C., and Di Napoli, R. (2022). Features, Evaluation, and Treatment of Coronavirus (COVID-19), StatPearls Publishing." }, { "key": "ref_34", "unstructured": "UpToDate (2022, August 10). COVID-19: Clinical Features. Available online: https://www.uptodate.com/contents/covid-19-clinical-features." }, { "key": "ref_35", "unstructured": "National Institutes of Health (2022, December 12). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, Available online: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf." }, { "DOI": "10.36472/msd.v9i6.749", "article-title": "A case of acute renal failure with COVID-19 under Molnupiravir treatment", "doi-asserted-by": "crossref", "first-page": "371", "journal-title": "Med. Sci. Discov.", "key": "ref_36", "volume": "9", "year": "2022" }, { "DOI": "10.3748/wjg.v28.i3.275", "article-title": "Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs", "author": "Tarnawski", "doi-asserted-by": "crossref", "first-page": "275", "journal-title": "World J. Gastroenterol.", "key": "ref_37", "volume": "28", "year": "2022" }, { "DOI": "10.1016/S2213-2600(20)30229-0", "article-title": "Management of acute kidney injury in patients with COVID-19", "author": "Ronco", "doi-asserted-by": "crossref", "first-page": "738", "journal-title": "Lancet Respir. Med.", "key": "ref_38", "volume": "8", "year": "2020" }, { "DOI": "10.1007/s13311-022-01267-y", "article-title": "Therapeutic Approaches to the Neurologic Manifestations of COVID-19", "author": "Graham", "doi-asserted-by": "crossref", "first-page": "1435", "journal-title": "Neurotherapeutics", "key": "ref_39", "volume": "19", "year": "2022" }, { "DOI": "10.1016/j.ccl.2022.03.001", "article-title": "The Cardiovascular Manifestations of COVID-19", "author": "Louis", "doi-asserted-by": "crossref", "first-page": "277", "journal-title": "Cardiol Clin.", "key": "ref_40", "volume": "40", "year": "2022" }, { "DOI": "10.54034/mic.e1366", "article-title": "Molnupiravir in Combination with Remdesivir for Severe COVID-19 Patients Admitted to Hospital: A Case Series", "author": "Hashemian", "doi-asserted-by": "crossref", "first-page": "e1366", "journal-title": "Microbes Infect. Chemother.", "key": "ref_41", "volume": "2", "year": "2022" } ], "reference-count": 41, "references-count": 41, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/2077-0383/12/1/34" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": "Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data", "type": "journal-article", "volume": "12" }